A carregar...

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Leelawat, Kawin, Narong, Siriluck, Wannaprasert, Jerasak, Leelawat, Surang
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE-Hindawi Access to Research 2011
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170848/
https://ncbi.nlm.nih.gov/pubmed/21994874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2011/873548
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!